4 days ago · The U.S. Food and Drug Administration approved twice-daily JOURNAVX for the treatment of adults with moderate-to-severe acute pain. Vertex has established a wholesale acquisition cost for JOURNAVX in the United States of $15.50 per 50mg pill. Vertex is also evaluating suzetrigine in peripheral neuropathic pain (PNP).

Vertex's painkiller was more effective than a placebo at reducing the intensity of pain after 48 hours in two late-stage studies on more than 1,000 patients who had abdominoplasties, also known as ...

3 days ago · Vertex’s drug works differently, blocking proteins that trigger pain signals that are later sent to the brain. “In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Vertex’s Dr. David Altshuler, told The Associated Press last year.

3 days ago · According to Vertex, every year, more than 80 million Americans are prescribed medicine to treat moderate-to-severe acute pain. About 40 million of them are prescribed opioids. Nearly 10% of acute pain patients prescribed an opioid as a first-line treatment will go on to use opioids long-term, and each year, about 85,000 patients will develop ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals. The drug, Journavx, or suzetrigine, was approved to treat moderate to severe ...

3 days ago · Vertex Pharmaceuticals has scored an FDA approval for Journavx (suzetrigine), a non-opioid pain reliever that could usher in a new era of nonaddictive therapy in the indication.. As an oral ...

3 days ago · Vertex’s new drug, which blocks the Nav1.8 channel, is highly specific — the other sodium channels are left alone by the drug. Suzetrigine’s effects disappear when people stop taking the pills.

4 days ago · Vertex hopes to eventually get the drug approved for chronic pain as well, though clinical trials testing it in that setting have produced mixed results. Acute pain is often treated with a combination of acetaminophen, anti-inflammatory agents like ibuprofen and, if necessary, opioids, which pose an addiction risk because they act directly on ...

3 days ago · Vertex says the drug is the first in a new class of pain medicine to be approved in more than 20 years. Its chief executive Reshma Kewalramani called the approval an "historic milestone for the 80 ...

Jan 30, 2024 · Vertex plans to submit a New Drug Application to the Food and Drug Administration (FDA) by mid-2024 with the goal of achieving a broad label in moderate-to-severe acute pain. VX-548 has secured Breakthrough Therapy and Fast Track designations in …